TEST:

MRDaccuPanel™ AML FLT3-ITD

"NGeneBio...launched MRDaccuPanel AML FLT3, an NGS-based ultra-sensitive gene diagnostics product to assist in the prescription of targeted therapies, monitor treatment, and predict relapse in acute myeloid leukemia (AML) patients."

"NGENBio...held the Korean Society of Laboratory Medicine held at the BEXCO Convention Hall in Busan from April 27 to 28. It was announced on the 27th that it would participate in the 2023 Spring Symposium...NgenBio plans to set up an exhibition booth at the event and promote its NGS precision diagnosis technology and new products to hospital officials, universities, corporate research institutes, and public institution officials who visited the site. In particular, HEMEaccuTest™, a precision diagnosis product for blood cancer, which is closely related to the topic of overseas speakers, will be introduced as the main focus...In addition, the FLT3-ITD test product (MRDaccuPanel™ AML FLT3-ITD) for acute myeloid leukemia (AML) micro-residual disease, which is scheduled to be released, will be introduced at this conference."